Epigenomics CEO Geert Nygaard has left the firm and Thomas Taapken has been appointed as sole member of the company's executive board, effective Oct. 1.
Taapken previously served as CFO at Epigenomics, a position he held since April 2011. He joined Epigenomics from Biotie Therapies in Finland, where he also served as CFO. He was appointed to this position in 2008, following a merger between Biotie Therapies and Elbion, where Taapken had been CFO since 2005. He has also held positions as an investment partner at Deutsche Venture Capital and Burrill & Company. Taapken also worked several years at Sanofi-Aventis.
Epigenomics has also promoted Uwe Staub, former senior vice president of research and development, to the position of COO.